Legal status · United States
Is Oxyntomodulin legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Oxyntomodulin is not an approved medicine in the United States; its classification is "Not a drug; endogenous hormone and research infusion peptide". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Oxyntomodulin in the United States at a glance
| Classification | Not a drug; endogenous hormone and research infusion peptide |
|---|---|
| Note | Drugs acting at its receptor are approved. The hormone itself is not a therapeutic. |
| FDA approval status | Not approved and not marketed anywhere. Its therapeutic relevance is as a design template. |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Oxyntomodulin profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Oxyntomodulin is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Oxyntomodulin is
Glucagon with eight extra amino acids on the end, which turns it into a weak dual agonist at both glucagon and GLP-1 receptors. The natural template for every GLP-1 and glucagon dual agonist.
Oxyntomodulin is the glucagon sequence plus an eight-residue tail, KRNRNNIA. That single structural fact explains its entire pharmacology and is why it belongs on this site.
Mechanism: A weak dual agonist at the glucagon receptor and the GLP-1 receptor, with no dedicated receptor. The proposed appeal of that combination is that GLP-1 receptor agonism suppresses appetite while glucagon receptor agonism raises energy expenditure, so the pair might reduce intake and increase output at once.
Regulatory history: Not approved and not marketed anywhere. Its therapeutic relevance is as a design template.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Oxyntomodulin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Oxyntomodulin in other countries
Frequently asked questions
Is Oxyntomodulin legal in the United States?
No. Oxyntomodulin is not an approved medicine in the United States; its classification is "Not a drug; endogenous hormone and research infusion peptide". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: Drugs acting at its receptor are approved. The hormone itself is not a therapeutic.
Can I buy Oxyntomodulin in the United States?
No approved product exists to buy. In the United States Oxyntomodulin is classified as "Not a drug; endogenous hormone and research infusion peptide", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Drugs acting at its receptor are approved. The hormone itself is not a therapeutic.
Is Oxyntomodulin FDA approved?
No. FDA status: Not approved and not marketed anywhere. Its therapeutic relevance is as a design template.. Current US classification: "Not a drug; endogenous hormone and research infusion peptide". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Oxyntomodulin live on its compound profile.
Oxyntomodulin profileThis page is general information about the regulatory status of Oxyntomodulin in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.